Clinical trial · Observational
Liquid Biopsy in Glioblastoma Treated With Chemoradiation and an Oxygen Therapeutic
NCT07417774CI-TRIAL-00103545RESTORE LBenrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this sub-study of the RESTORE trial is to identify biomarkers associated with tumor hypoxia, identify biomarkers that differentiate pseudoprogression from true progression, and correlate biomarkers with clinical outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma (GBM) | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Tumor hypoxia biomarkers
- timeFrame
- until disease progression and up to 5 years
- description
- Identify differentially expressed tumor hypoxia markers in newly-diagnosed glioblastoma subjects treated with NanO2 versus placebo in the RESTORE study.
Secondary outcomes (2)
- measure
- Biomarker expression
- timeFrame
- until disease progression and up to 5 years
- description
- To measure differentially expressed biomarkers that distinguish pseudoprogression from true progression
- measure
- Relationship between biomarker levels, MGMT methylation status, and survival outcomes
- timeFrame
- until disease progression and up to 5 years
- description
- Evaluate whether biomarker levels are associated with MGMT promoter methylation status and how long study participants live without their disease getting worse (Progression-Free Survival) and how long they live overall (Overall Survival). This will help determine whether the biomarkers may predict patient outcomes.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Subjects must be enrolled in the RESTORE study (NCT03862430) and provide written informed consent for the RESTORE LB sub-study
References
Publications (0)
Data not yet available
No reference posted for this study.